Anti–Diabetic Activity of Murraya koenigii – A Comprehensive Review

U. Vidhya Rekha *

Department of Public Health Dentistry, Sree Balaji Dental College and Hospital, Chennai, India.

S. Bhuminathan

Department of Prosthodontics, Sree Balaji Dental College and Hospital, Chennai, India.

P. Ravi Shankar

Department of Public Health Dentistry, Rajas Dental College and Hospital, Kavalkinaru, Tirunelveli Dist, India.

*Author to whom correspondence should be addressed.


Abstract

Diabetes mellitus, one of the noncommunicable illnesses, is a severe problem worldwide as one of the leading causes of death. Because existing synthetic medications have various drawbacks, researchers are still looking for better anti-hyperglycemic treatments. Plants have been used in ancient medicine for thousands of years. India is the biggest producer of medicinal plants and is aptly regarded as the "World's Botanical Garden." Murraya koenigii Linn, also known as Meethi neem, is a Rutaceae plant. Curry trees are unique to India and likely found almost everywhere else on the subcontinent, except in the Himalayan highlands. For centuries, curry leaves were used as an antiemetic, diarrhea remedy, febrifuge, and blood purifier. Curry leaves are useful as an antioxidant, anti-diabetic, antibacterial, antihypertensive, cytotoxic, and in treating bronchial respiratory problems. Traditionally, the leaves were utilized as a spice in curries as well as other dishes. It includes coumarins and derivatives, alkaloids, flavonoids, phenolic compounds, and essential oil. Numerous studies have found that these phytochemicals have a significant effect on type 2 diabetes. This review focuses on this plant's anti-diabetic action and concludes that it has the potential to be evaluated as a candidate for developing a new diabetes mellitus medication.

Keywords: Medicinal plants, Murraya koenigii, diabetes mellitus


How to Cite

Rekha, U. V., Bhuminathan, S. and Shankar, P. R. (2021) “Anti–Diabetic Activity of Murraya koenigii – A Comprehensive Review”, Journal of Pharmaceutical Research International, 33(58B), pp. 462–470. doi: 10.9734/jpri/2021/v33i58B34226.